Inhibikase Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Inhibikase Therapeutics, Inc. (IKT) had Lessee, Operating Lease, Liability, to be Paid, Year One of $38.32 thousand as of 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2024-11-14
- 2024-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $38.32K.
- 2024-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $75.58K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2024-09-30 | $38.32K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $75.58K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |